T1	Participants 94 115	in diabetic patients:
T2	Participants 337 440	in diabetic patients after sirolimus-eluting stent (SES) or paclitaxel-eluting stent (PES) implantation
T3	Participants 473 552	Diabetic patients with de novo coronary lesions (169 patients with 190 lesions)
